Tags

Type your tag names separated by a space and hit enter

Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy.
Clin Exp Allergy. 2012 Oct; 42(10):1510-8.CE

Abstract

BACKGROUND

The impact of sublingual immunotherapy (SLIT) on IgE neosensitization remains to be evaluated in large cohorts of patients.

OBJECTIVES

The aim of this study was to assess the dynamics of antibody responses induced in patients with allergic rhinitis during a 12-month treatment with sublingual tablets of house dust mites (HDM) allergen extracts.

METHODS

Antibody responses were assessed in relationship with neosensitization and clinical benefit in sera from 509 European house dust mite-allergic patients before and after 1 year of daily sublingual immunotherapy, using tablets containing Dermatophagoides pteronyssinus plus D farinae extracts or placebo (ClinicalTrials.gov NCT00674700). Patients were followed for one additional year after treatment cessation. IgE and IgG4 antibodies specific for mite extracts or purified group 1, 2 and 10 allergens were assessed using Immulite, Immunocap and ISAC assays.

RESULTS

After 1 year of SLIT, mite-specific IgE and IgG4 titres increased by 1.5-fold and fourfold, respectively, in the active, but not in the placebo group. A strong IgG4 induction occurred in a subgroup (i.e. 10-15%) of "immunoreactive" patients, without any correlation with improvement in the average adjusted symptom score. Pre-existing IgE levels to purified mite allergens were not impacted during immunotherapy, and no de novo IgE responses to group 1, 2, 10 allergens were induced in patients who were unsensitized prior to immunotherapy. Similarly, no IgE neosensitization to wheat germ or yeast components used in the mite culture medium was observed.

CONCLUSIONS AND CLINICAL RELEVANCE

We document in a cohort of 509 patients followed over a 2-year period that SLIT does not induce any IgE neosensitization to allergens contained in the vaccine, such as groups 1, 2 as well as the food-related group 10 allergen. This observation further corroborates the safer safety profile of SLIT over SCIT.

Authors+Show Affiliations

Stallergenes SA, 6 rue Alexis de Tocqueville, 92183, Antony Cedex, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase II
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

22994348

Citation

Baron-Bodo, V, et al. "Absence of IgE Neosensitization in House Dust Mite Allergic Patients Following Sublingual Immunotherapy." Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, vol. 42, no. 10, 2012, pp. 1510-8.
Baron-Bodo V, Batard T, Nguyen H, et al. Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clin Exp Allergy. 2012;42(10):1510-8.
Baron-Bodo, V., Batard, T., Nguyen, H., Fréreux, M., Horiot, S., Harwanegg, C., Bergmann, K. C., de Beaumont, O., & Moingeon, P. (2012). Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 42(10), 1510-8. https://doi.org/10.1111/j.1365-2222.2012.04044.x
Baron-Bodo V, et al. Absence of IgE Neosensitization in House Dust Mite Allergic Patients Following Sublingual Immunotherapy. Clin Exp Allergy. 2012;42(10):1510-8. PubMed PMID: 22994348.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Absence of IgE neosensitization in house dust mite allergic patients following sublingual immunotherapy. AU - Baron-Bodo,V, AU - Batard,T, AU - Nguyen,H, AU - Fréreux,M, AU - Horiot,S, AU - Harwanegg,C, AU - Bergmann,K C, AU - de Beaumont,O, AU - Moingeon,P, PY - 2012/9/22/entrez PY - 2012/9/22/pubmed PY - 2013/3/9/medline SP - 1510 EP - 8 JF - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology JO - Clin. Exp. Allergy VL - 42 IS - 10 N2 - BACKGROUND: The impact of sublingual immunotherapy (SLIT) on IgE neosensitization remains to be evaluated in large cohorts of patients. OBJECTIVES: The aim of this study was to assess the dynamics of antibody responses induced in patients with allergic rhinitis during a 12-month treatment with sublingual tablets of house dust mites (HDM) allergen extracts. METHODS: Antibody responses were assessed in relationship with neosensitization and clinical benefit in sera from 509 European house dust mite-allergic patients before and after 1 year of daily sublingual immunotherapy, using tablets containing Dermatophagoides pteronyssinus plus D farinae extracts or placebo (ClinicalTrials.gov NCT00674700). Patients were followed for one additional year after treatment cessation. IgE and IgG4 antibodies specific for mite extracts or purified group 1, 2 and 10 allergens were assessed using Immulite, Immunocap and ISAC assays. RESULTS: After 1 year of SLIT, mite-specific IgE and IgG4 titres increased by 1.5-fold and fourfold, respectively, in the active, but not in the placebo group. A strong IgG4 induction occurred in a subgroup (i.e. 10-15%) of "immunoreactive" patients, without any correlation with improvement in the average adjusted symptom score. Pre-existing IgE levels to purified mite allergens were not impacted during immunotherapy, and no de novo IgE responses to group 1, 2, 10 allergens were induced in patients who were unsensitized prior to immunotherapy. Similarly, no IgE neosensitization to wheat germ or yeast components used in the mite culture medium was observed. CONCLUSIONS AND CLINICAL RELEVANCE: We document in a cohort of 509 patients followed over a 2-year period that SLIT does not induce any IgE neosensitization to allergens contained in the vaccine, such as groups 1, 2 as well as the food-related group 10 allergen. This observation further corroborates the safer safety profile of SLIT over SCIT. SN - 1365-2222 UR - https://www.unboundmedicine.com/medline/citation/22994348/Absence_of_IgE_neosensitization_in_house_dust_mite_allergic_patients_following_sublingual_immunotherapy_ L2 - https://doi.org/10.1111/j.1365-2222.2012.04044.x DB - PRIME DP - Unbound Medicine ER -